Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 94, Issue 1, 2001, Pages 86-91

  Rozenberg, Serge ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hormone replacement therapy; Menopause; Oestrogen; Progestogen

Indexed keywords

ESTROGEN; PROGESTERONE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENDOMETRIUM CANCER; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; TREATMENT INDICATION; UTERUS BLEEDING; VASCULAR DISEASE;

EID: 0035180604     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(00)00301-8     Document Type: Article

References (39)

1. Benefits and risks of hormone replacement therapy (HRT)
2. Estrogen replacement therapy: Indications, contraindications, and agent selection
3. Combined continuous hormone replacement therapy: A critical review
4. Hormone replacement therapy: Aspects of bleeding problems and compliance
5. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women
6. Why do postmenopausal women discontinue hormone replacement therapy?
7. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
8. The menopause and osteoporosis
9. Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestogen regimens in post-menopausal women
10. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient
11. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment
12. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen-progestin interventions (PEPI) trial
13. The lack of effect of progestogen on bone
14. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen-Progestin Interventions (PEPI) Trial
15. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
16. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen-progestogen therapy
17. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women
18. Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen-Progestin Interventions (PEPI) Trial
19. Women's opinion on withdrawal bleeding with hormone replacement therapy
20. Micronized 17β-estradiol for oral estrogen therapy in menopausal women
21. Use of low-dosage 17β-estradiol for the prevention of osteoporosis
22. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives
23. A review of post-marketing safety and surveillance data for oral contraceptives containing norgestimate and ethinyl estradiol
24. Regulation of estrogen-progestogen receptors in the endometrium
25. Human endometrial cells in primary tissue culture: Modulation of the progesterone receptor level by natural and synthetic estrogens in vitro
26. Relationship between the quantity of progesterone receptor and the antagonism of estrogen-induced uterotropic response
27. Effects of various types and dosages of progestogens on the postmenopausal endometrium
28. Progesterone-mediated suppression of estradiol receptors in cynomolgus macaque cervix, endometrium and oviduct during sequential estradiol-progesterone treatment
29. Short-term effects of tamoxifen, medroxyprogesterone acetate, and their combination on receptor kinetics and 17β-hydroxysteroid dehydrogenase in human endometrium
30. Estrogen and interrupted progestin: A new concept for menopausal hormone replacement therapy
31. Rapid recovery of nuclear estrogen receptor and oxytocin receptor in the ovine uterus following progesterone withdrawal
32. The effect of a unique constant-estrogen pulsed-progestin hormone replacement therapy containing 17β-estradiol and norgestimate on endometrial histology
33. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy
34. A novel pulsed regimen of norgestimate preserves the beneficial effects of 17β-estradiol on lipids and lipoproteins
35. Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy
36. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women
37. The effect of three hormone replacement regimens on bone density in the aged ovariectomized rat
38. Enzymatic modulation of hormonal action at the target tissue
39. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium